Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
NCT01722227 on ClinicalTrials.gov · last registry update 2017-02-09
Withdrawn before anyone was enrolled. Its estimated completion date, November 2017, has passed with no update to the record. Primary outcome, as filed: Mean weekly blood glucose concentrations. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- WITHDRAWN
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University at Buffalo
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2012-11
- Primary completion
- 2017-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean weekly blood glucose concentrations.
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.